About Anthony Catalano
Anthony Catalano has served as Chief Operating Officer since May 2026, providing strategic leadership for the organization’s operations in support of its long-term growth, performance, and execution priorities. Drawing on extensive experience in operations, supply chain management, and cross-functional leadership, he oversees initiatives that enhance efficiency, strengthen scalability, and advance alignment across critical business functions.
Prior to joining Quanterix, Anthony served as SVP of Real Estate and Asset Management at Flagship Pioneering where he led the global real estate and facilities teams overseeing >2M square feet of laboratory and office space. Previously, Anthony held a senior leadership role at Akoya Biosciences, where he led operations, R&D, and served as integration leader for the 2025 merger with Quanterix. As SVP of Operations and R&D at IsoPlexis, he led the organization through its 2023 merger with Berkeley Lights forming PhenomeX after a successful IPO in 2021. Earlier, at PerkinElmer, Anthony held senior leadership roles with responsibility for operations across 20 sites in eight countries, overseeing manufacturing, supply chain, and integration activities supporting more than $1 billion in global life sciences, food safety, and COVID diagnostic products. Earlier in his career he held roles of increasing responsibility at VisEn Medical, which was acquired by PerkinElmer in 2010, Nova Biomedical and Etex Corporation.
Anthony holds a M.S. in Chemistry from Brandeis University, and a B.S. in Chemistry from the University of Massachusetts.
